MiR-200c restored the sensitivity of HER2-positive breast cancer to trastuzumab by targeting ZNF217/TGF-β/ZEB1 axis and suppressing CSC-like phenotype (260, 261). This evidence concerns the gene ZEB1 and breast carcinoma.